Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications
Role of molecular driver mutations in recurrence of early-stage laryngeal cancer following narrow field definitive radiotherapy.
Journal: Oral oncology reports
Published: May 13, 2026
Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology.
Journal: The Lancet. Oncology
Published: February 13, 2026
GTV Expert Opinion: "Between a parotid bed and a skull place: third course of reirradiation is a charm".
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: February 05, 2026
Advancing Proton Therapy: Integration of Minibeam Spatial Fractionation and FLASH Dose Rates.
Journal: Research square
Published: December 11, 2025
Biologically Effective Dose-Optimized Multi-Intensity-Modulated Proton Therapy: A Biologically Comparable Alternative to Proton Arc Therapy.
Journal: International journal of particle therapy
Published: December 08, 2025
Proton-Based Chemoradiation With Conventional Fractionation and Systemic Therapy for Failure.
Journal: International journal of radiation oncology, biology, physics
Published: December 01, 2025
Experimental characterization of proton minibeam therapy delivery under FLASH dose-rate conditions.
Journal: Scientific reports
Published: November 14, 2025
Radiation-Induced Fibrosis (RIF) in Head and Neck Squamous Cell Carcinoma (HNSCC): A Review.
Journal: Cells
Published: October 21, 2025
Spread-Out Bragg Peak FLASH Radiotherapy for Head and Neck Reirradiation: A Treatment Planning Study.
Journal: International journal of particle therapy
Published: September 30, 2025
Targeting notch signaling pathway in esophageal cancer: from molecular insights to therapies.
Journal: Oncology reviews
Published: September 19, 2025
A Randomized Phase II Trial of Hypo-fractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction Versus Standard- Fractionated IMRT, Concurrent With Carboplatin/Paclitaxel and Followed by Consolidation Durvalumab, for Subjects With Stage III Non-Small Cell Lung Cancer.
Journal: Clinical lung cancer
Published: September 11, 2025
MK2 promotes p16 negative head and neck cancer migration, invasion, and metastasis.
Journal: Cancer letters
Published: February 03, 2025
Last Updated: 09/26/2026